[Form 4] NEUROCRINE BIOSCIENCES INC Insider Trading Activity

Neurocrine Biosciences (NBIX) reported an insider transaction.

Rhea-AI Filing Summary

Neurocrine Biosciences (NBIX) reported an insider transaction. On 11/05/2025, a director exercised 18,000 non-qualified stock options at an exercise price of $47.89 per share and sold 18,000 common shares at a weighted average price of $151.8161. The sale was executed under a Rule 10b5-1 trading plan adopted on August 6, 2025.

Following these transactions, the reporting person beneficially owned 40,360 shares, held by the Rastetter Family Trust. The option was granted on May 20, 2016 and was due to expire on May 20, 2026.

Insider Trade Summary

Exercise and Sale: 18,000 shares ($1.87M approx. pre-tax spread)

Exercise and Sale 3 txns

Insider RASTETTER WILLIAM H

Role Director

Sold 18,000 shs ($2.73M)

Approx. gross sale proceeds $2.73M

Approx. exercise cost $862K

Approx. pre-tax spread $1.87M

Type	Security	Shares	Price	Value
Exercise	Non-Qualified Stock Option	18,000	$0.00	$0.00
Exercise	Common Stock	18,000	$47.89	$862K
Sale	Common Stock	18,000	$151.8161	$2.73M

Holdings After Transaction: Non-Qualified Stock Option — 0 contracts (Direct); Common Stock — 40,360 shares (Direct)

Footnotes (4)

1. F1. The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on August 6, 2025. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
2. F2. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $150.00 to $153.01. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
3. F3. 40,360 of the reported shares are held by the Rastetter Family Trust established September 2, 2010, of which the Reporting Person has voting and investment power.
4. F4. The option was granted May 20, 2016 and vested in 12 equal monthly installments beginning June 20, 2016. These options were due to expire on May 20, 2026.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did NBIX disclose in this Form 4?

A director exercised 18,000 stock options at $47.89 and sold 18,000 shares at a weighted average of $151.8161 on 11/05/2025.

Was the NBIX insider sale under a 10b5-1 plan?

Yes. The sale was made pursuant to a Rule 10b5-1 trading plan adopted on August 6, 2025.

How many NBIX shares does the insider own after the transaction?

The reporting person beneficially owned 40,360 shares following the transactions, held by the Rastetter Family Trust.

What price range were the NBIX shares sold at?

Sales occurred in multiple transactions at prices ranging from $150.00 to $153.01.

What were the terms of the exercised NBIX option?

It was a non-qualified stock option with a $47.89 exercise price, granted on May 20, 2016, and due to expire on May 20, 2026.

Who signed the NBIX Form 4?

It was signed by /s/ Darin Lippoldt, Attorney-in-Fact on 11/06/2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/06/2025 - 05:25 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

RASTETTER WILLIAM H

(Last) (First) (Middle)

6027 EDGEWOOD BEND CT.

(Street)

SAN DIEGO CA 92130

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
NEUROCRINE BIOSCIENCES INC [ NBIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/05/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/05/2025		M		18,000	A	$47.89	58,360	D
Common Stock	11/05/2025		S(1)		18,000	D	$151.8161(2)	40,360(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Qualified Stock Option	$47.89	11/05/2025		M			18,000	(4)	05/20/2026	Common Stock	18,000	$0	0	D

Explanation of Responses:

1. The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on August 6, 2025. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

2. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $150.00 to $153.01. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

3. 40,360 of the reported shares are held by the Rastetter Family Trust established September 2, 2010, of which the Reporting Person has voting and investment power.

4. The option was granted May 20, 2016 and vested in 12 equal monthly installments beginning June 20, 2016. These options were due to expire on May 20, 2026.

Remarks:

	/s/ Darin Lippoldt, Attorney-in-Fact	11/06/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.